

Current landscape of ESMO/ASCO Global Curriculum adoption and Medical Oncology recognition: A global survey

Tanja Cufer¹, Michael Kosty², Pia Osterlund^{3,4}, Svetlana Jezdic⁵, Doug Pyle⁶, Ahmad Awada⁷, Julia Close⁸, Nagi El-Saghir⁹, Florian Lordick¹⁰, Piotr Rutkowski¹¹, Arafat Tfayli⁹, Hans Wildiers¹²

¹ Medical Faculty, University of Ljubljana, Ljubljana, Slovenia, ² Division of Hematology/Oncology, Scripps Clinic, La Jolla, California, USA, ³ Department of Oncology, Tampere University Hospital and University of Tampere, Tampere, Finland, ⁴ Department of Oncology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁵ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland, ⁶ International Affairs, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA, ⁷ Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium, ⁸ University of Florida College of Medicine, Gainesville, FL, USA, ⁹ Department of Internal Medicine, NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon, ¹⁰ Department of Oncology, University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany, ¹¹ Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland, ¹² Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

Background

Medical Oncology (MO) is one of the basic disciplines of multidisciplinary cancer care.

A Global Curriculum (GC) developed and updated by a joint ESMO/ASCO GC Task Force/Working Group (GC WG) greatly contributed to the recognition of MO worldwide.

Methods

ESMO/ASCO GC WG performed a global survey on MO recognition and GC adoption in 2019.

The survey was developed by the GC WG and sent to the ESMO national representative, national society or the leader of the training programme in countries with whom either ESMO or ASCO had official relations at that time.

Figure 1. Recognition of Medical Oncology





Figure 2. ESMO/ASCO GC adoption



Results

- MO is recognised as specialty or sub-specialty in 47/62 (75%) of participating countries, in vast majority (39/47, 83%) as a specialty.
- In 9/62 (15%) of countries MO is trained together with haematology, as haemato-oncology) or radiotherapy, as clinical oncology (Figure 1).
- ESMO/ASCO GC has been either fully or partially adopted or adapted in two-thirds of participating countries (Figure 2).

Conclusions

- Based on survey, MO is recognised and ESMO/ASCO GC has been adopted/adapted in a vast majority of countries, without major differences observed around the world.
- This most comprehensive information will definitely support further dissemination of MO and GC worldwide.

Medical Oncology recognised as specialty	Medical Oncology recognised as sub-specialty	Clinical Oncology	Haemato-Oncology	Medical Oncology NOT recognised	Global Curriculum fully adopted	Global Curriculum partly adopted	Global Curriculum adapted	Global Curriculum followed, but training take place abroad	Global Curriculum NOT adopted
Argentina Bangladesh Belgium Bosnia and Herzegovina Brazil Bulgaria China Croatia Cyprus Czech Republic Egypt France Ghana* Greece Honduras* Hungary Iceland** India Ireland Israel	Italy Kenya Latvia Lithuania Luxembourg* Mexico Montenegro* Myanmar** New Zealand Poland Portugal Romania Serbia Singapore Slovak Republic Slovenia Spain Switzerland United States of America	Bangladesh Croatia Denmark Egypt Estonia Finland Ghana Honduras* Iceland** Luxembourg* Malaysia Sweden Zambia	Austria Germany Honduras* Iceland** Lebanon Luxembourg*	Albania Armenia Belarus Kazakhstan North Macedonia Russian Federation	Belgium Brazil Croatia Greece Japan Kenya Lithuania New Zealand Panama Serbia Slovak Republic Spain	Bosnia and Herzegovina Cyprus Czech Republic Egypt Hungary Indonesia Italy* Latvia Mexico Philippines Portugal Saudi Arabia Slovenia South Africa Turkey United States of America	Albania Armenia Belarus Kazakhstan Lebanon North Macedonia Myanmar Russian Federation Sweden	Ghana Honduras Iceland Luxembourg Montenegro	Argentina Bangladesh Bulgaria Canada China Denmark Estonia France India Ireland Israel Malaysia Poland Romania Singapore Zambia

*Training abroad

**Duration shorter than recommended by Global Curriculum

* Not in the whole country, but some training centres follow it

All other countries without information



Acknowledgements: The authors thank to all colleagues who responded to the questionnaire, to Christian Dittich, past chair of ESMO/ASCO GC WG for landscape conception and help in data interpretation and to ESMO staff for their support in data collection/ management and analysis.

Funding: ESMO and ASCO (no grant number) were the legal sponsors of the project. No research funding was received from any third parties.